Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient preference-based phosphate binder therapy in hemodialysis
NL-OMON25073Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2020
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label trial of sevelamer carbonate, lanthanum carbonate and iron sucrose in hyperphosphatemia, chronic kidney disease (CKD) and end-stage kidney disease (ESKD), sponsored by Amsterdam University Medical Center. Primary endpoint: Patient satisfaction with phosphate treatment. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
sevelamer carbonatelanthanum carbonateiron sucrose
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NL-OMON25073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25073.